United States Patent 4,724,232 (3′-azido-3′-deoxythymidine) Scope, Claim Construction Levers, and US Patent Landscape
US Drug Patent 4,724,232 claims methods of treating HIV/AIDS using oral or parenteral 3′-azido-3′-deoxythymidine (AZT; zidovudine) including multiple dosage-form embodiments and salt forms. The independent claim set is directed to (i) acquired immunodeficiency syndrome (AIDS) treatment using AZT by defined routes and (ii) AIDS-related complex (ARC) treatment using AZT by defined routes. The dependent claims expand the scope through route-specific and formulation-specific limitations (capsules, tablets, aqueous/non-aqueous solutions and suspensions; sterile injectable formulation; and pharmaceutically acceptable alkali metal, alkaline earth, or ammonium salts).
What does US patent 4,724,232 claim: method-of-treatment scope for AZT in AIDS and ARC?
Core scope (independent claim logic):
- Claims a method of treating a human with AIDS by administering an “effective” treatment amount of 3′-azido-3′-deoxythymidine.
- Claims a parallel method of treating a human with AIDS-related complex (ARC) by administering an “effective” treatment amount of 3′-azido-3′-deoxythymidine.
- The independent claims are structured around route of administration:
- Oral administration (AIDS and ARC sets).
- Parenteral administration with a sterile injectable formulation (AIDS and ARC sets).
- Administration of AZT or a pharmaceutically acceptable salt (AIDS and ARC sets), with oral or parenteral administration.
Featured-snippet answer: The patent covers administering AZT (zidovudine) to treat AIDS or ARC in humans by oral dosing forms and by parenteral dosing in sterile injectable formulations, including embodiments using AZT salts.
How is “effective treatment amount” used across the claims?
The claims use functional language: “an effective acquired immunodeficiency syndrome treatment amount” and “an effective … related complex treatment amount.” That phrasing is typical of method claims where the amount is not numerically specified.
Business implication:
- In infringement analysis, this typically becomes a factual/technical question tied to clinical dosing ranges and “effective” therapeutic activity, rather than a hard mg constraint.
Does the patent claim AZT free base only or also salts?
Yes. Claims include “3′-azido-3′-deoxythymidine or a pharmaceutically acceptable alkali metal, alkaline earth or ammonium salt thereof” (claims 8–12 and 20–24).
Key scope points:
- Salt classes are limited to alkali metal, alkaline earth, and ammonium salts.
- The salt must be “pharmaceutically acceptable” and the administration must be “oral or parenteral” per the independent structure.
What are the specific claim elements and limitations for claim 1 (AIDS, oral AZT)?
Claim 1 is the anchor:
- Treat a human with AIDS.
- By oral administration.
- Administer an “effective … treatment amount” of 3′-azido-3′-deoxythymidine.
Claim 1 contains no explicit formulation limitation. That matters because dependent claims then enumerate specific dosage forms (capsules/tablets/aqueous or non-aqueous solutions or suspensions).
How do claims 2–6 expand oral scope into dosage forms?
These dependent claims convert the broad “oral administration” into specific presentations:
- Claim 2: capsule
- Claim 3: tablet
- Claim 4: aqueous solution
- Claim 5: aqueous suspension
- Claim 6: non-aqueous suspension
Business implication:
- These create multiple infringement “routes” for a generic or branded product by formulation category.
- If AZT is administered orally but not in one of these dosage-form categories, the dependent claims may be avoided while the broader independent claim 1 could still be asserted if the formulation still falls within “oral administration” using an effective dose.
What is the parenteral scope: claim 7 and sterile injectable formulation requirements?
Claim 7:
- Treat a human with AIDS.
- By parenteral administration.
- Using an “effective” AZT amount.
- In a sterile injectable formulation.
Key limitation:
- “Sterile injectable formulation” is a manufacturing/clinical form requirement. It narrows the method to parenteral presentations that are sterile and injectable.
Business implication:
- A product route that is not “parenteral” or not “sterile injectable” (as claimed) could reduce risk under claim 7 while leaving oral claims unaffected.
What does claim 8 cover: AZT salts and route flexibility?
Claim 8:
- Treat a human with AIDS.
- Administer AZT or a pharmaceutically acceptable salt (alkali metal, alkaline earth, ammonium).
- The administration is not limited to oral only in claim 8.
Then:
- Claim 9 specifies that the compound is administered orally or parenterally.
- Claim 10 limits: “in which the salt is administered” (meaning the administered species is the salt rather than the free base).
- Claim 11 specifies admin form: a tablet, capsule, or sterile injectable formulation containing AZT or the salt.
- Claim 12 specifies solution/suspension types for oral: aqueous or non-aqueous solution or suspension.
Business implication:
- Claim 8–12 create multiple formulation buckets across salt vs free base, route vs presentation, and dosage form.
What do the ARC claims add: treatment of AIDS-related complex with AZT?
The ARC section is a near mirror image of the AIDS section, with independent claims for oral and parenteral administration and salt coverage.
- Claim 13: ARC treated by oral administration of AZT.
- Claims 14–18: ARC oral dosage forms (capsule, tablet, aqueous solution, aqueous suspension, non-aqueous suspension).
- Claim 19: ARC treated by parenteral administration of AZT in a sterile injectable formulation.
- Claim 20: ARC treated by administering AZT or specified pharmaceutically acceptable salts.
- Claims 21–24: route (oral or parenteral), salt admin, dosage forms (tablet/capsule/sterile injectable), and oral solution/suspension types.
Business implication:
- This expands enforcement surface because claims are tied to ARC in addition to AIDS. In regulatory and clinical practice, modern labeling language has shifted over time, but method claims still focus on the indication definitions used at filing.
How broad are the claim categories relative to product designs?
Breadth drivers
- “effective … amount” is not numerically limited.
- “oral administration” is not limited by excipients or manufacturing parameters in the independent claims.
- Salt claims are defined by salt class (alkali, alkaline earth, ammonium), not by a single specific counterion.
Breadth constraints
- Dependent claims require particular dosage-form categories.
- Parenteral claims require “sterile injectable formulation.”
- Salt claims require salts within specific categories and “pharmaceutically acceptable.”
What is the likely claim construction center of gravity (for infringement and invalidity positioning)?
1) “3′-azido-3′-deoxythymidine” identity
The active is explicitly defined. No prodrug substitution is in the literal claim language.
2) Indication terms: “AIDS” and “AIDS-related complex”
In litigation, these are often litigated as claim construction and evidentiary issues:
- Whether the defendant’s labeled or off-label use meets the claimed clinical state.
- How the definition maps onto clinical criteria used historically.
3) “Oral” vs “parenteral”
Route characterization matters:
- Oral: covers capsules/tablets and solutions/suspensions.
- Parenteral: limited to sterile injectable formulations.
4) Salt administration
For salt infringement, the administered species must correspond to a “pharmaceutically acceptable” alkali/alkaline earth/ammonium salt, not arbitrary salts.
US patent landscape around AZT (zidovudine) methods: what patents typically co-exist with claim scope like 4,724,232?
A credible landscape view for AZT generally includes:
- Core composition and stabilized forms (drug substance and specific formulations).
- Method-of-use patents (AIDS/ARC treatment; dosing regimens; combination therapy concepts).
- Pharmaceutical formulation patents (tablets, capsules, oral liquids; parenteral sterile compositions).
- Manufacturing process patents (synthetic routes and purification steps).
Given the claim set you provided, 4,724,232 is a method-of-treatment patent, not a composition-by-itself claim in the abstract. Its practical importance in freedom-to-operate is that it can capture:
- Any AZT-based oral dosing to treat AIDS/ARC, including dosage form variants enumerated in dependent claims.
- Sterile injectable AZT intended for AIDS/ARC.
- AZT salt formulations within the claimed salt class.
What infringement theories are strongest under 4,724,232?
Best-fit infringement scenarios
- A product label or physician practice administering AZT to treat AIDS or ARC by:
- oral capsule/tablet/solution/suspension, or
- sterile injectable AZT for parenteral treatment.
- A product that uses AZT as the active ingredient (not a prodrug) and delivers an “effective amount.”
Design-around leverage
The dependent claims create multiple “touchpoints,” but the independent claims remain relatively broad:
- Avoiding specific dosage forms may still leave oral administration covered by claim 1 (for AIDS) or claim 13 (for ARC).
- Avoiding sterile injectable formulations may reduce exposure for claims 7 and 19, but not for oral claims.
Salt-based designs:
- Switching to counterions outside “alkali metal, alkaline earth, or ammonium” could be relevant to claims 8–12 and 20–24 if salt administration is central.
- Using AZT free base instead of a claimed salt could help if the asserted claim is limited to “salt is administered” (claim 10) and “salt-containing formulations” (claim 11 context).
How does 4,724,232 compare with other AZT patent types (and why does that matter for strategy)?
Because 4,724,232 is anchored to method-of-treatment, its threat profile differs from formulation or composition patents:
- Method-of-use patents can still matter even if a generic’s product composition is not identical, because the claim is triggered by use in a human to treat the claimed condition.
- Formulation patents require product-specific infringement features.
- Composition/substance patents can bar supplying or making the API, while method claims often hinge on labeling, instructions, and evidence of intended use.
Strategic consequence:
- A generic that supplies AZT may be more exposed under method-of-use claims if it markets for the claimed indications or if physician evidence ties actual use to AIDS/ARC.
Key takeaways on claim scope and business exposure
- 4,724,232 covers AZT as a therapeutic active for AIDS and AIDS-related complex.
- It is organized into oral and parenteral administration pathways.
- Dependent claims enumerate multiple oral dosage forms (capsule, tablet, aqueous/non-aqueous solution/suspension).
- Parenteral coverage requires sterile injectable formulations.
- Salt embodiments extend coverage to alkali metal, alkaline earth, or ammonium salts of AZT and include both route and dosage form limitations.
Key Takeaways
- US 4,724,232 is a method-of-use patent focused on administering 3′-azido-3′-deoxythymidine (zidovudine/AZT) to humans to treat AIDS and ARC.
- The independent claims cover oral administration and parenteral administration (sterile injectable formulation) and “AZT or pharmaceutically acceptable salt.”
- Dependent claims multiply infringement vectors through capsules, tablets, aqueous/non-aqueous solutions and suspensions, and through salt-based embodiments.
- For enforcement or clearance strategy, the actionable levers are route, dosage form category, whether a claimed salt is administered, and evidence tying use to AIDS/ARC.
FAQs
1) Does 4,724,232 cover AZT prodrugs or only AZT (3′-azido-3′-deoxythymidine) itself?
The claims are limited to 3′-azido-3′-deoxythymidine (AZT) and specified salts of that compound.
2) Are oral solutions and suspensions covered even if the dependent claims are not asserted?
Oral formulations are covered at the broader level by the independent oral claims, with dependent claims explicitly listing solution/suspension categories.
3) What is the practical significance of “sterile injectable formulation” in claim 7 and 19?
It narrows parenteral coverage to AZT presentations that are sterile and injectable, creating a compliance and evidence focus for any parenteral product.
4) Can a product avoid salt-based claim elements by using a different counterion?
Salt-dependent claims are limited to alkali metal, alkaline earth, or ammonium salts, so counterions outside those classes may reduce coverage under salt-specific limitations.
5) Which claim set is broader, the AIDS set or ARC set?
They are substantially parallel in structure; both cover oral administration, parenteral sterile injections, and salt embodiments with corresponding dependent dosage-form listings.
References (APA)
- United States Patent No. 4,724,232.
